Pooled analyses of randomized controlled trials onpyrotinib plus capecitabine and a rethink of the first-line options for HER2-positive relapsed or metastatic breast cancer  

作　　者：Xiuwen Guan Fei Ma Binghe Xu 

机构地区：[1]Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China [2]Department of Medical Oncology and Clinical Trial Center,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,China

出　　处：《Cancer Innovation》2022年第2期119-123,共5页肿瘤创新（英文）

基　　金：National Nature Science Foundation of China,Grant/Award Number:8210114934;CAMS Innovation Fund for Medical Sciences,Grant/Award Numbers:CIFMS,2021-I2M-1-014。

摘　　要：Human epidermal growth factor receptor 2(HER2)-positive breast cancer,which accounts for 15%-20% of breast cancers,is associated with aggressive tumor behavior and conferred a poor outcome before the era of HER2-targeted therapy.The advent of anti-HER2 antibodies(trastuzumab and pertuzumab),antibody-drug conjugates(ADCs,ado-trastuzumab emtansine and trastuzumab deruxtecan),and HER2‐tyrosine kinase inhibitors(TKIs,neratinib and lapatinib),have dramatically improved the treatment response and survival of this aggressive subtype.

关 键 词：breast cancer tyrosine kinase inhibitor HER2-targeted therapy 

分 类 号：R737.9[医药卫生—肿瘤]